Hoth Therapeutics Inc. (HOTH)
NASDAQ (CM) NASDAQ (CM) Primary Summary
HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal
Hoth stock soars as a mid-stage study meets the goal, showing significant improvement in skin toxicities related to EFGR inhibitor therapy in all HT-001-treated patients.
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
Why Is Hoth Therapeutics (HOTH) Stock Moving Today?
Hoth Therapeutics (NASDAQ: HOTH ) stock is on the move Wednesday after the clinical-stage biopharmaceutical company announced a new partnership with LTS Therapy Systems. This partnership has the two companies working together to accelerate the development of Hoth Therapeutics' candidate for Alzheimer's disease.
Hoth Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA Marie-Andree Alain Federation des caisses Desjardins du Quebec | 350 | $350 | $525 | $175 | 50% |
Hoth Therapeutics Inc. (HOTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Hoth Therapeutics Inc. ever had a stock split?
Hoth Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robb Knie CEO | NASDAQ (CM) Exchange | 44148G105 CUSIP |
| US Country | 2 Employees | - Last Dividend | 26 Oct 2022 Last Split | 15 Feb 2019 IPO Date |
Overview
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to addressing unmet medical needs through the development of novel therapies. Established in 2017 and headquartered in New York, New York, the company is engaged in the discovery and development of therapeutic solutions across a broad range of conditions, including skin disorders, cancers, neuroinflammatory diseases, asthma, allergies, acne, psoriasis, and COVID-19. Through collaborations with esteemed institutions and leveraging proprietary platforms, Hoth Therapeutics aims to bring innovative treatments to market, focusing on both direct therapeutic interventions and supportive diagnostic tools.
Products and Services
- HT-001: A topical formulation in Phase II clinical trial designed to alleviate rash and skin disorders related to tyrosine kinase epidermal growth factor receptor inhibitor therapy.
- HT-KIT: Targets mast-cell derived cancers and anaphylaxis, showcasing Hoth Therapeutics' commitment to addressing rare and severe allergic reactions.
- HT-TBI: Focused on the treatment of traumatic brain injury and ischemic stroke, aiming to provide solutions for acute neurological conditions.
- HT-ALZ: Developed for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases, demonstrating the company's venture into neurodegenerative disorders.
- HT-004: Offers a method for treating asthma and allergies through inhalational administration, highlighting innovative delivery mechanisms.
- HT-003: Addresses acne, psoriasis, and potentially inflammatory bowel diseases, underlining the versatility of Hoth Therapeutics' therapeutic platforms.
- HT-002: A novel peptide for the treatment of COVID-19, reflecting the company's rapid response to emerging global health crises.
- BioLexa Platform: A proprietary, patented drug compound platform in Phase I trial for treating eczema, exemplifying the company's commitment to dermatological conditions.
- HT-005: Aimed at treating patients with lupus, expanding the company's portfolio into autoimmune diseases.
- Diagnostic Device: A mobile device-based diagnostic tool, showcasing Hoth Therapeutics' efforts in integrating diagnostic and therapeutic solutions.
In addition to its product pipeline, Hoth Therapeutics has established key license agreements and research collaborations with prestigious institutions such as the George Washington University, Isoprene Pharmaceuticals, Inc., Virginia Commonwealth University, North Carolina State University, Chelexa BioSciences, Inc. and the University of Cincinnati, Zylö Therapeutics, Inc., and Voltron Therapeutics, Inc. The company's partnership with Weill Cornell Medicine to develop HT-003 further highlights its engagement with leading research entities to advance its therapeutic objectives.
